We adopt a collaborative model to develop and apply novel cell-based phenotypic assay technologies across disease areas.
The IGMM Phenotypic Discovery Facility is highly proficient in cell-based phenotypic screening, working in collaboration with several academic and industry groups to identify; novel therapeutics targets, progress hit-to-lead identification, classify drug mechanism-of-action and identify novel drug combinations and biomarkers.
The facility members have several years of experience in the development and execution of complex cell and ex-vivo screening assays across multiple disease areas from within the academic and pharmaceutical industry sectors.
The facility is equipped with the latest kinetic (IncuCyte-Zoom) and High content (ImageXpress MicroXL) image-based screening platforms, fully integrated with plate handling robotics, barcode sample tracking and an image-analysis and informatics pipeline operating across the IGMM computer cluster.
In addition to using proprietary high content image analysis software solutions, the facility develops and applies novel image analysis and informatics solutions to quantify cellular phenotypes from complex co-culture and 3D models and to classify phenotypes from multi-parametric datasets.
The facility has libraries of annotated reference compounds, FDA approved drugs, novel compound sets and a 12,000 diverse chemical library. The compound libraries are optimally stored and managed at Bioascent Discoveries Ltd facilities and supplied to our projects as single use, assay-ready plates.
|John Dawson||Head of High Content Imaging and Informatics|
|Ashraff Makda||Head of Screening Operations|
|Professor Neil Carragher||Professor of Drug Discovery|
For more information on the services provided within the facility, please contact: